Hepion Pharmaceuticals Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
HEPA
- Investments
-
2
- Share Price
-
$0.11
- (As of Friday Closing)
Hepion Pharmaceuticals General Information
Description
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.
Contact Information
Website
www.hepionpharma.comCorporate Office
- 399 Thornall Street
- 1st Floor
- Edison, NJ 08837
- United States
Corporate Office
- 399 Thornall Street
- 1st Floor
- Edison, NJ 08837
- United States
Hepion Pharmaceuticals Stock Performance
As of 13-Nov-2026, Hepion Pharmaceuticals’s stock price is $0.11. Its current market cap is $14.1M with 123M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.11 | $0.14 | $0.03 - $0.22 | $14.1M | 123M | 38.8K | -$0.19 |
Hepion Pharmaceuticals Financials Summary
As of 30-Jun-2026, Hepion Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,068 | 286 | 5,693 | (3,293) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (3,188) | (8,253) | (14,884) | (49,258) |
| Net Income | (3,188) | (8,278) | (13,192) | (48,926) |
| Total Assets | 1,927 | 3,070 | 1,614 | 18,094 |
| Total Debt | 0 | 54 | 2,900 | 209 |
Hepion Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hepion Pharmaceuticals Comparisons
Industry
Financing
Details
Hepion Pharmaceuticals Competitors (2)
One of Hepion Pharmaceuticals’s 2 competitors is Madrigal Pharmaceuticals, a Formerly VC-backed company based in West Conshohocken, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Formerly VC-backed | West Conshohocken, PA | ||||
| Intercept Pharmaceuticals | Formerly VC-backed | Morristown, NJ |
Hepion Pharmaceuticals Patents
Hepion Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024285817-A1 | Solid state forms of rencofilstat | Pending | 08-Jun-2023 | ||
| EP-4724081-A2 | Solid state forms of rencofilstat | Pending | 08-Jun-2023 | ||
| WO-2024254480-A2 | Solid state forms of rencofilstat | Inactive | 08-Jun-2023 | ||
| WO-2024254480-A3 | Solid state forms of rencofilstat | Inactive | 08-Jun-2023 | ||
| AU-2021388171-A1 | Use of cyclosporine analogues as antithrombotic agents | Pending | 29-Nov-2020 | A61K38/13 |
Hepion Pharmaceuticals Signals
Hepion Pharmaceuticals Acquisitions (2)
Hepion Pharmaceuticals’s most recent deal was a Merger/Acquisition with Gravitas Life Sciences. The deal was made on 06-Oct-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Gravitas Life Sciences | 06-Oct-2026 | Merger/Acquisition | Pharmaceuticals | ||
| Ciclofilin Pharmaceuticals | 10-Jun-2016 | Merger/Acquisition | Drug Discovery |
Hepion Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated March, 31, 2026
43.03 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
Hepion Pharmaceuticals FAQs
-
When was Hepion Pharmaceuticals founded?
Hepion Pharmaceuticals was founded in 2013.
-
Where is Hepion Pharmaceuticals headquartered?
Hepion Pharmaceuticals is headquartered in Edison, NJ.
-
What is the size of Hepion Pharmaceuticals?
Hepion Pharmaceuticals has 2 total employees.
-
What industry is Hepion Pharmaceuticals in?
Hepion Pharmaceuticals’s primary industry is Biotechnology.
-
Is Hepion Pharmaceuticals a private or public company?
Hepion Pharmaceuticals is a Public company.
-
What is Hepion Pharmaceuticals’s stock symbol?
The ticker symbol for Hepion Pharmaceuticals is HEPA.
-
What is the current stock price of Hepion Pharmaceuticals?
As of 13-Nov-2026 the stock price of Hepion Pharmaceuticals is $0.11.
-
What is the current market cap of Hepion Pharmaceuticals?
The current market capitalization of Hepion Pharmaceuticals is $14.1M.
-
Who are Hepion Pharmaceuticals’s competitors?
Madrigal Pharmaceuticals and Intercept Pharmaceuticals are competitors of Hepion Pharmaceuticals.
-
What is Hepion Pharmaceuticals’s annual earnings per share (EPS)?
Hepion Pharmaceuticals’s EPS for 12 months was -$0.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process